CTRI/2010/091/000484已完成3 期
A multicentre,single blind, comparative clinical trial to compare the efficacy and safety of FDC of cefoperazone and tazobactam and cefoperazone alone in infections caused by Gm(-ve) organisms.
Ms Kilitch DrugsIndia Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Male and female subjects in the aged group of 18-60 years shall be selected.
- •2. Clinically diagonised subjects with gm (-ve) infections with culture showing the organisms.
- •3. Subjects willing to give informed consent.
- •4. Patient must not have received any antibiotics in previous 4 weeks.
排除标准
- •1. History of hypersensitivity reaction or any specific groups.
- •2. Presence of severe hepatic or renal disorders.
- •3. Pregnancy or lactation.
- •4. History of hearing loss.
- •5. Previous history seizure.
- •6. Alcoholic.
研究者
相似试验
已完成
3 期
A multicentric, randomized, comparative clinical trial of Armodafinil versus Modafinil in patients with excessive sleepiness associated with shift work sleep disorder (SWSD).CTRI/2009/091/000617Emcure Pharmaceuticals Ltd Pune.
进行中（未招募）
1 期
A multicentre, randomised, double-blind, comparative trial of a novel CCR5 antagonist, UK427,857, in combination with zidovudine/lamivudine versus efavirenz in combination with zidovudine/lamivudine for the treatment of antiretroviral-naïve HIV-1 infected subjectsK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.MedDRA version: 14.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestationsEUCTR2004-001914-15-GBViiV Healthcare UK Limited891
进行中（未招募）
1 期
A multicentre, randomised, double-blind, comparative trial of a novel CCR5 antagonist, UK427,857, in combination with zidovudine/lamivudine versus efavirenz in combination with zidovudine/lamivudine for the treatment of antiretroviral-naïve HIV-1 infected subjects.K-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.EUCTR2004-001914-15-ESPfizer S.A1,071
进行中（未招募）
不适用
A double-blind, randomised, multicenter, comparativestudy of escitalopram and duloxetine in outpatients withMajor Depressive DisorderEUCTR2004-005069-39-DEH. Lundbeck A/S260
进行中（未招募）
1 期
A double-blind, randomised, multicenter, comparativestudy of escitalopram and duloxetine in outpatients withMajor Depressive DisorderMajor depressive disorderEUCTR2004-005069-39-SEH. Lundbeck A/S260